Combination: proliferating tumor cells and immune effector cells

The 'Combination: proliferating tumor cells and immune effector cells' refers to a therapeutic strategy rather than a single molecular target. This approach involves the use of multispecific agents, such as Bispecific T-cell Engagers (BiTEs), to physically bridge malignant cells with cytotoxic immune cells like T cells or Natural Killer (NK) cells (Huehls et al., 2015, Immunology and Cell Biology). By binding simultaneously to a tumor-associated antigen and a triggering receptor on the effector cell (e.g., CD3), these agents induce the formation of an immunological synapse, bypassing the requirement for MHC-restricted antigen presentation (Labrijn et al., 2019, Nature Reviews Drug Discovery). This interaction leads to the activation of the immune cell and the subsequent release of perforins and granzymes, resulting in the lysis of the proliferating tumor cell. While highly effective in treating hematologic malignancies like B-cell precursor acute lymphoblastic leukemia, this strategy is frequently associated with systemic inflammatory toxicities, most notably Cytokine Release Syndrome (CRS) and neurotoxicity (Shimabukuro-Vornhagen et al., 2018, Journal for ImmunoTherapy of Cancer). Consequently, this 'target' represents a functional pairing used to redirect the host's immune system against cancer. It is a cornerstone of modern immunotherapy, particularly for patients with relapsed or refractory disease.

Other names

T-cell redirectionTumor-immune synapse inductionBispecific T-cell engager (BiTE) mechanismImmune effector cell recruitmentImmune synapse formation

Simultaneous binding of a tumor-associated antigen and an immune cell trigger (e.g., CD3), facilitating an immunological synapse and direct cytotoxic killing of the tumor cell.